Aurinia Pharmaceuticals Inc. (AUPH)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150M 300M 450M Q3 '21: 72.2M Q4 '21: 45.6M Q1 '22: 66.3M Q2 '22: 87.9M Q3 '22: 129M Q4 '22: 134M Q1 '23: 146.8M Q2 '23: 160.1M Q3 '23: 158.9M Q4 '23: 175.5M Q1 '24: 191.4M Q2 '24: 207.1M Q3 '24: 220.4M Q4 '24: 235.1M Q1 '25: 247.3M Q2 '25: 260.1M Q3 '25: 265.8M Q4 '25: 283.1M Q1 '26: 298.3M Q2 '26: 311.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 100M 200M 300M Q3 '21: 71.6M Q4 '21: 44.5M Q1 '22: 65M Q2 '22: 85.3M Q3 '22: 124.2M Q4 '22: 128.4M Q1 '23: 141M Q2 '23: 154.3M Q3 '23: 148.7M Q4 '23: 161.4M Q1 '24: 169.9M Q2 '24: 178.3M Q3 '24: 192.3M Q4 '24: 206.9M Q1 '25: 218.2M Q2 '25: 232.8M Q3 '25: 236.4M Q4 '25: 250.4M Q1 '26: 267.7M Q2 '26: 281.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-210M -140M -70M 0 70M 140M 210M Q3 '21: -156.1M Q4 '21: -180.7M Q1 '22: -168.1M Q2 '22: -156.9M Q3 '22: -116.1M Q4 '22: -111.5M Q1 '23: -103.2M Q2 '23: -83.4M Q3 '23: -90.1M Q4 '23: -91.7M Q1 '24: -75.4M Q2 '24: -60.7M Q3 '24: -32.7M Q4 '24: -4.7M Q1 '25: 30.4M Q2 '25: 52M Q3 '25: 70M Q4 '25: 104.9M Q1 '26: 124.5M Q2 '26: 150.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-300M -150M 0 150M 300M 450M Q3 '21: -155.7M Q4 '21: -181M Q1 '22: -168.2M Q2 '22: -156.7M Q3 '22: -115.5M Q4 '22: -108.2M Q1 '23: -96.8M Q2 '23: -72.7M Q3 '23: -77.2M Q4 '23: -78M Q1 '24: -62.6M Q2 '24: -50.3M Q3 '24: -22.6M Q4 '24: 5.8M Q1 '25: 39.8M Q2 '25: 60.6M Q3 '25: 77.8M Q4 '25: 287.2M Q1 '26: 298.2M Q2 '26: 314.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 15M 30M 45M Q3 '21: 610K Q4 '21: 1.1M Q1 '22: 1.3M Q2 '22: 2.6M Q3 '22: 4.8M Q4 '22: 5.7M Q1 '23: 5.8M Q2 '23: 5.8M Q3 '23: 10.1M Q4 '23: 14.1M Q1 '24: 21.5M Q2 '24: 28.8M Q3 '24: 28.1M Q4 '24: 28.2M Q1 '25: 29.1M Q2 '25: 27.3M Q3 '25: 29.4M Q4 '25: 32.7M Q1 '26: 30.6M Q2 '26: 30M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -128.6M Q4 '21: -157.7M Q1 '22: -150.9M Q2 '22: -140.8M Q3 '22: -115.9M Q4 '22: -79.5M Q1 '23: -64.5M Q2 '23: -39.4M Q3 '23: -37.3M Q4 '23: -33.5M Q1 '24: -20.4M Q2 '24: -1.7M Q3 '24: 28.6M Q4 '24: 44.4M Q1 '25: 64.3M Q2 '25: 92.7M Q3 '25: 120.1M Q4 '25: 135.7M Q1 '26: 166.9M Q2 '26: 175.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -130.4M Q4 '21: -158M Q1 '22: -151.1M Q2 '22: -140.8M Q3 '22: -116.1M Q4 '22: -79.8M Q1 '23: -65M Q2 '23: -40.1M Q3 '23: -37.9M Q4 '23: -34.2M Q1 '24: -20.8M Q2 '24: -2.1M Q3 '24: 28.1M Q4 '24: 44.1M Q1 '25: 64M Q2 '25: 92.4M Q3 '25: 119.9M Q4 '25: 135.4M Q1 '26: 166.6M Q2 '26: 175.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '20: 112.6M Q3 '20: 122.4M Q1 '21: 127.4M Q2 '21: 128.2M Q3 '21: 128.4M Q1 '22: 141.7M Q2 '22: 141.7M Q3 '22: 141.9M Q1 '23: 142.6M Q2 '23: 142.8M Q3 '23: 142.8M Q1 '24: 144M Q2 '24: 144.1M Q3 '24: 145.7M Q1 '25: 143.2M Q2 '25: 137.5M Q3 '25: 136M Q1 '26: 137.6M Q2 '26: 133.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.60 -0.80 0.00 0.80 1.60 2.40 Q3 '21: -1.22 Q4 '21: -1.41 Q1 '22: -1.28 Q2 '22: -1.16 Q3 '22: -0.83 Q4 '22: -0.76 Q1 '23: -0.67 Q2 '23: -0.50 Q3 '23: -0.53 Q4 '23: -0.54 Q1 '24: -0.43 Q2 '24: -0.34 Q3 '24: -0.15 Q4 '24: 0.05 Q1 '25: 0.28 Q2 '25: 0.43 Q3 '25: 0.56 Q4 '25: 2.08 Q1 '26: 2.17 Q2 '26: 2.29 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.